RARE
Ultragenyx Pharmaceutical, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website ultragenyx.com
- Employees(FY) 1311
- ISIN US90400D1081
Performance
+1.58%
1W
-1.04%
1M
-14.41%
3M
+7.5%
6M
-12.44%
YTD
-14.81%
1Y
Profile
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111 (ABO-102), an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.
Investment Analysis Report: RARE
Overview
In this investment analysis report, we will analyze the stock of RARE, a company operating in the Health Technology sector within the Pharmaceuticals: Major industry. We will delve into the financial health, earnings and revenue growth, profitability, operating margin, operating cash flow analysis, and c...
Technical Analysis of RARE 2024-05-10
Overview:
In analyzing the technical indicators for RARE over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key indicators, we aim to offer valuable insights and predictions for informed deci...
Recent News & Updates
- 2024-04-12 16:22
- 2024-04-12 08:00
- 2024-04-12 04:22
- 2024-04-11 20:00
- 2024-03-22 16:00
- 2024-03-22 04:00
- 2024-03-20 08:11
10 NASDAQ Stocks with Biggest Upside(Insider Monkey)
- 2024-03-19 20:11
10 NASDAQ Stocks with Biggest Upside(Insidermonkey)
- 2024-03-12 17:00
- 2024-03-11 15:00
- 2024-03-08 09:38
10 Biotech Stocks with Huge Potential(Insider Monkey)
- 2024-02-27 16:30
Ultragenyx to Participate at Investor Conferences in March(GlobeNewswire)
- 2024-02-27 03:30
Ultragenyx to Participate at Investor Conferences in March(Globenewswire)
- 2024-02-23 16:05
- 2024-02-23 03:05
- 2024-02-17 08:23
- 2024-02-16 10:43
- 2024-02-16 10:35
Q4 2023 Ultragenyx Pharmaceutical Inc Earnings Call(Thomson Reuters StreetEvents)
- 2024-02-16 07:53
- 2024-02-15 21:43
- 2024-02-15 16:15
Ultragenyx: Q4 Earnings Snapshot(Associated Press Finance)
- 2024-02-15 16:01
- 2024-02-15 03:01
- 2024-02-13 13:36
15 Best Strong Buy Stocks To Invest In(Insider Monkey)
- 2024-02-08 16:00
- 2024-02-08 03:00
- 2024-02-06 08:00
- 2024-02-05 19:00
- 2024-02-05 16:05
- 2024-02-05 03:05